Lecanemab is an injection that targets harmful proteins in the brain known as Amyloid-beta (Aβ) which have been linked to Alzheimer's disease. The clinical trial included people between the ages of 50 and 90 who had been diagnosed with mild memory loss or mild dementia caused by Alzheimer's disease.
Alzheimer's is a debilitating brain disease that can cause memory problems and mild cognitive impairment. People living with moderate to severe Alzheimer's can have issues with their ability to carry things or walk, and this gets worse over time. The exact cause of the disease is not fully understood, but it is thought to be a combination of genetic, lifestyle, and environmental risk factors.
Approximately 5-6 million Americans are currently living with Alzheimer's disease and this number is projected to rise to nearly 14 million by 2050. The disease primarily affects those who are 65 or older, however, it's not uncommon to develop the disease in one's 40s or 50s.
Are you interested in clinical trials near you?
You can receive free notification of a trial for this, or any other condition, by completing a short confidential health profile. Find a clinical trial near me
Clinical Trial Results
In this research study, half of the participants were given Lecanemab treatment, while the other half were given a placebo. This was a double-blind clinical study, meaning that neither the participants nor the scientists knew who was getting which treatment until the end of the study. The study was done for 18 months, and the scientists looked at how much the participants' memory and thinking skills changed over that time.
The results of this clinical research showed that persons with Alzheimer's who received the Lecanemab treatment had less decline in their thinking and memory skills compared to the people with Alzheimer's who received the placebo. However, a test that measures a patient’s ability to perform daily activities did not show any statistically significant difference between the two groups. The trial was a phase 3 trial, meaning that it was the last step before seeking approval from the Food and Drug Administration for the drug.
Overall, the trial shows that Lecanemab has the potential to slow down the progression of Alzheimer's in people with early stages of the disease, while also lowering the amyloid burden in the brain. This is an exciting breakthrough for people affected by Alzheimer's disease; however, more research needs to be done to confirm these findings and to determine the safety and long-term effects of the treatment.
This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content.
Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition.
Assistance from generative AI tools may have been used in writing this article.